Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, today announced its operational and financial
results for the second quarter ended June 30, 2022.
“Autolus has had a successful second quarter,
with progress made across all fronts. We were awarded Regenerative
Medicine Advanced Therapy (RMAT) Designation for obecabtagene
autoleucel (obe-cel) for the treatment of adult acute lymphoblastic
leukemia (ALL) by the US Food and Drug Administration (FDA) in
April 2022, showcased cell programming technology at the American
Society of Gene and Cell Therapy (ASGCT) meeting in May 2022, and
announced first clinical data from four pipeline programs at the
European Hematology Association (EHA) congress in June 2022. During
this time, we also continued to progress the pivotal Phase 2 FELIX
clinical trial of obe-cel in r/r ALL, and the build of our
commercial manufacturing site is progressing on schedule,”
said Dr. Christian Itin, CEO of Autolus. “Obe-cel
continues to show very encouraging activity with a high level of
sustained complete remissions in B-NHL patients, without inducing
severe CRS or neurotoxicity, and AUTO1/22 reached clinical proof of
concept with a high level of activity observed in children with ALL
who are not eligible for commercial CAR T therapy. We are
particularly excited about AUTO4 reaching clinical proof of concept
in patients with T cell lymphoma. We are looking forward to
releasing initial results for the FELIX trial in Q4 2022 and are
planning updates on our other clinical studies at the end of the
year.”
Key Pipeline Updates:
- Obecabtagene autoleucel (obe-cel)
in relapsed / refractory (r/r) adult ALL
- The FELIX Phase 2 trial continues to progress well, and Autolus
is on track to report initial results from the trial in Q4 2022.
The Company continues to expect to report full data in H1
2023, with plans to present this data at a medical conference
in mid-2023.
- Following the RMAT designation granted to obe-cel in April 2022
by FDA, Autolus met with the FDA to review the regulatory pathway
for obe-cel in r/r ALL. Consistent with prior guidance, and
assuming a positive outcome from the FELIX trial in H1 2023, the
Company expects the data to form the basis of a planned Biologics
License Application (BLA) submission to FDA.
- As previously announced, Autolus initiated a separate cohort of
up to 50 additional patients with Minimal Residual Disease (MRD),
with the intention of establishing the profile of obe-cel in
patients across all levels of disease burden in adult ALL.
Pipeline updates at the European
Hematology Congress (EHA), June 2022:
- Obe-cel shows high level of
sustained clinical activity in r/r B-NHL patients – ALLCAR19
Extension Trial
- Patients continue to be enrolled
into the Phase 1 ALLCAR19 extension trial. The latest data readout
from this extension study of obe-cel in patients with r/r B-Cell
Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukemia
(CLL) were presented at EHA in June 2022. In this patient
population, obe-cel continues to display a favorable safety profile
with no neurotoxicity/immune effector cell-associated neurotoxicity
(ICANS) or Grade ≥ 3 Cytokine Release Syndrome (CRS). Long term
persistence of obe-cel in the peripheral blood was demonstrated by
qPCR. Of the 20 patients evaluable for efficacy, the overall
response rate was 18/20 (90%). In the B-NHL cohorts the CRR was
16/17 (94%) (FL: 7/7, MCL: 3/3, DBCL: 6/7). In the CLL cohort 2/3
patients achieved a PR, notably both achieved MRD-negativity in
their marrow and both remain in PR at 10 and 6 months respectively.
Of the responding MCL, DLBCL, FL and CLL patients, 17/18 (94%) are
without disease progression at last follow-up. One MCL patient
relapsed six months following treatment and 1 FL patient died in CR
from COVID-19. Longer follow-up and enrolment of additional MCL,
FL, DLBCL and CLL patients is ongoing.
- Obe-cel shows first activity in
Primary CNS Lymphoma – CAROUSEL Trial
- Patients continue to be enrolled
into the Phase 1 CAROUSEL trial. Data from the trial were presented
at EHA in June 2022, where excellent expansion was observed in the
peripheral blood by qPCR, with persistence in all treated patients
at last follow-up. No Grade 3 or higher CRS was observed using IV
or I-VEN AUTO1 administration. Two cases of Grade 3 ICANS were
reported following IV infusion. In the first case the patient had
several neurological deficits that evolved despite ICANS treatment
and were compatible with progressive PCNSL, as confirmed with the
month 1 MRI scan. The second case was a patient whose neurological
deficits improved with steroids/anakinra. Encouraging response
rates were observed: of 6 patients evaluable for efficacy following
IV AUTO1, the ORR was 4/6 (67%), with 2 CRs and 2 PRs. These four
responding patients are without disease progression at last follow
up. Two patients died from progressive PCNSL on study.
- AUTO1/22 in pediatric ALL
demonstrates encouraging and durable responses in children
ineligible for commercial CAR T product – CARPALL Trial
- Autolus, in collaboration with UCL,
continues to enroll patients into the AUTO1/22 Phase 1 CARPALL
trial. The results from 11 treated patients, who were ineligible
for receiving commercial CAR T therapy, were presented in an oral
presentation at EHA in June 2022. AUTO1/22 has demonstrated a
favorable safety profile with no incidences of severe CRS, and one
Grade 4 ICANS which was indistinguishable from chemotherapy-related
leukoencephalopathy. We have seen excellent CAR T expansion, with
only 4 patients losing CAR T persistence at the last follow up.
Overall, 9 out of 11 patients achieved a molecular complete
response, with 2 non-responders. Notably, 2 out of 3 patients with
CD19-negative disease achieved molecular complete response
demonstrating the efficacy of the CD22 CAR. Two patients relapsed
with CD19+CD22+ disease. No antigen negative relapses were seen in
responding patients. At a median follow up of 8.7 months, 6 of 9
responding patients were in MRD-negative complete remission (1-12
months) and the median duration of B-cell aplasia has not been
reached.
- AUTO4 shows high level of clinical
activity with a novel targeting approach for patients with T Cell
Lymphoma – LibrA T1 Trial
- Autolus continues to enroll
patients into the AUTO4 Phase 1 clinical trial. Interim Phase 1
data were presented as an oral presentation at EHA in June 2022
from 10 patients with TRBC1-positive r/r T-cell lymphoma
(Peripheral T-cell lymphoma Not Otherwise Specified (PTCL-NOS),
Angioimmunoblastic T-cell lymphoma (AITL), Anaplastic Large cell
lymphoma (ALCL)) in a Phase 1 dose escalation trial. The median
prior lines of treatment was 3 (1-5) and three patients had prior
stem cell transplantation. After lymphodepletion with Flu/Cy,
patients received either 25, 75, 225 or 450 x 106 CAR T cells.
AUTO4 demonstrated a tolerable safety profile, with no patient
experiencing any dose limiting toxicities, and no ICANS and no
Grade 3 or higher infections. CRS was only seen at the highest dose
level of 450 x 106 CAR T cells (Grade 3 in 1 patient; Grade 1-2 in
3 patients). As of April 26, 2022, 9 patients were evaluable for
efficacy. At the highest dose level 3 of the 3 patients dosed
achieved a complete metabolic remission (CMR) at 1 month. 2 of
these patients remain in ongoing CMR by PET-CT at Month 3 and 6
respectively, whilst the 3rd relapsed at 3 months.
Other pipeline updates:
- AUTO8 in Multiple Myeloma – MCARTY
Trial
- Autolus, in collaboration with UCL,
initiated a Phase 1 clinical trial of AUTO8, the Company’s
next-generation product candidate for multiple myeloma, in Q1 2022,
with the first patient dosed during the quarter. AUTO8 comprises
two independent CARs targeting BCMA and CD19 designed to induce
deep and durable responses and extend the durability of
effect.
- Autolus presented three abstracts
at the American Society of Gene & Cell Therapy (ASGCT) meeting
in May 2022. The three abstracts focused on Autolus’ modular
approach to CAR T product development, using innovative technology
to improve our pipeline of precise, controlled and highly active
products. The three abstracts covered: 1) enhancing CAR T therapy
using constitutively active cytokine receptors, 2) engineering CAR
T cells to express a Fas-CD40 to increase its persistence and tumor
cytotoxicity and 3) developing a minocycline mediated
protein-protein displacement platform to make cell therapies
tunable, dose dependent and reversible.
Key Operational Updates during Q2
2022
- The build phase of the Company’s
new 70,000 square foot commercial manufacturing facility in
Stevenage, UK continues to progress on track with the anticipated
schedule. This facility is expected to be ready for Good
Manufacturing Practice (GMP) operations by H2 2023 and is designed
for a capacity of 2,000 batches per year with the option to expand
capacity as needed.
Key Anticipated Clinical
Milestones:
- Initial clinical results from the
pivotal FELIX Phase 2 trial in Q4 2022 and Autolus plans to present
full data at a medical meeting in H1 2023.
- Longer-term follow up data from
Phase 1 ALLCAR19 extension trial of obe-cel in patients with r/r
B-NHL and CLL planned in H2 2022.
- Longer-term follow up data from
Phase 1 CAROUSEL trial of obe-cel in patients with Primary CNS
Lymphoma planned in 2023.
- Longer-term follow up data from the
Phase 1 CARPALL extension trial of AUTO1/22 in pediatric ALL
patients planned in H2 2022.
- Longer-term follow up data from
Phase 1 LibrA T1 trial of AUTO4 in patients with Peripheral T Cell
Lymphoma planned in H2 2022.
- AUTO6NG Phase 1 clinical trial in
patients with neuroblastoma expected to start H2 2022. First data
is expected in H2 2023.
- AUTO8 Phase 1 MCARTY clinical trial
in patients with multiple myeloma has started, with the first
patient dosed. First data is expected in H2 2023.
Financial Results for the Quarter Ended June 30,
2022
Cash at June 30, 2022, totaled $216.4 million,
as compared to cash of $310.3 million at December 31, 2021.
Total operating expenses for the three months
ended June 30, 2022, were $46.5 million, as compared to total
operating expenses, net of grant income and license revenue of $1.6
million, of $37.7 million for the same period in 2021.
Research and development expenses increased by
$6.1 million to $38.2 million from $32.1 million for the three
months ended June 30, 2022 as compared to the same period in 2021.
The net increase in research and development expenses of $6.1
million was primarily due to:
- an increase of $3.5
million in clinical costs and manufacturing costs primarily
relating to the obe-cel clinical product candidate,
- an increase of $1.4
million in salaries and other employment related costs including
share-based compensation expense, which is mainly driven by an
increase in the number of employees engaged in research and
development activities,
- an increase of $1.4
million in legal fees and professional consulting fees in relation
to the Company’s research and development activities,
- an increase of $0.5
million related to information technology infrastructure and
support for information systems related to the conduct of clinical
trials and manufacturing operations,
- a decrease of $0.5
million in facilities costs related to the termination and closure
of the Company’s US manufacturing facility in 2021 and shift in its
manufacturing strategy, and
- a decrease of $0.2
million in depreciation and amortization related to property, plant
and equipment and intangible assets.
General and administrative expenses increased by
$1.1 million to $8.3 million for the three months ended June 30,
2022 from $7.2 million for the three months ended June 30, 2021
primarily due to:
- an increase of $1.3
million in salaries and other employment related costs including
share-based compensation expenses, which was mainly driven by an
increase in the number of employees engaged in general and
administrative activities,
- an increase of $0.1
million primarily related to higher directors' and officers'
liability insurance premiums, professional fees and information
technology costs,
- a decrease of $0.2
million in facilities costs related to the termination by the
Company of certain lease agreements in the prior year, and
- a decrease of $0.1
million in depreciation and amortization related to property, plant
and equipment and intangible assets.
Other expense, net decreased by $0.5 million to
$1.3 million for the three months ended June 30, 2022 from $1.8
million for the three months ended June 30, 2021, relating
primarily due to the strengthening of the U.S. dollar exchange rate
relative to the pound sterling.
Interest expense increased to $1.8 million for
the three months ended June 30, 2022 and relates to the liability
related to sales of future royalties and sales milestones which
arose upon the Company’s entry into the strategic collaboration and
financing agreement with Blackstone, in November 2021. There was no
interest expense during the comparable period in 2021.
Income tax benefit increased by $1.1 million to
$7.5 million for the three months ended June 30, 2022 from $6.4
million for the three months ended June 30, 2021 due to an increase
in qualifying research and development expenditures for the
quarter.
Net loss attributable to ordinary shareholders
was $42.1 million for the three months ended June 30, 2022, as
compared to $33.2 million for the same period in 2021. The basic
and diluted net loss per ordinary share for the three months ended
June 30, 2022, totaled $(0.46) compared to a basic and diluted net
loss per ordinary share of $(0.47) for the three months ended June
30, 2021.
Autolus estimates that its current cash on hand
and anticipated milestone payments from Blackstone extends the
Company’s runway into 2024.
Unaudited Financial Results for
the Quarter Ended June 30, 2022
Condensed Consolidated Balance Sheets (In
thousands, except share and per share amounts)
|
June 30,2022 |
|
December 31,2021 |
Assets |
|
|
|
Current
assets: |
|
|
|
Cash |
$ |
216,437 |
|
|
$ |
310,338 |
|
Restricted cash |
|
325 |
|
|
|
338 |
|
Prepaid expenses and other assets, current |
|
42,198 |
|
|
|
36,276 |
|
Total current assets |
|
258,960 |
|
|
|
346,952 |
|
Property and equipment,
net |
|
33,794 |
|
|
|
33,541 |
|
Prepaid expenses and other
non-current assets |
|
1,888 |
|
|
|
2,362 |
|
Operating lease right-of-use
assets |
|
15,230 |
|
|
|
18,775 |
|
Long-term deposits |
|
1,835 |
|
|
|
2,039 |
|
Deferred tax asset |
|
2,244 |
|
|
|
1,826 |
|
Intangible assets, net |
|
25 |
|
|
|
65 |
|
Total
assets |
$ |
313,976 |
|
|
$ |
405,560 |
|
Liabilities and
shareholders' equity |
|
|
|
Current
liabilities: |
|
|
|
Accounts payable |
$ |
162 |
|
|
$ |
431 |
|
Accrued expenses and other liabilities |
|
31,360 |
|
|
|
23,667 |
|
Operating lease liabilities |
|
3,995 |
|
|
|
4,453 |
|
Total current liabilities |
|
35,517 |
|
|
|
28,551 |
|
Operating lease liabilities,
net of current portion |
|
13,208 |
|
|
|
16,545 |
|
Liability related to sale of
future royalties and sales milestones, net |
|
50,615 |
|
|
|
47,016 |
|
Other long-term payables |
|
115 |
|
|
|
128 |
|
Total
liabilities |
|
99,455 |
|
|
|
92,240 |
|
|
|
|
|
Commitments and contingencies
(Note 12) |
|
|
|
|
|
|
|
Shareholders'
equity: |
|
|
|
Ordinary shares, $0.000042 par value; 290,909,783 and 200,000,000
shares authorized as of June 30, 2022 and December 31, 2021,
respectively; 90,909,783 and 90,907,830, shares issued and
outstanding at June 30, 2022 and December 31, 2021,
respectively |
|
4 |
|
|
|
4 |
|
Deferred shares, £0.00001 par value; 34,425 shares authorized,
issued and outstanding at June 30, 2022 and December 31,
2021 |
|
— |
|
|
|
— |
|
Deferred B shares, £0.00099 par value; 88,893,548 shares
authorized, issued and outstanding at June 30, 2022 and
December 31, 2021 |
|
118 |
|
|
|
118 |
|
Deferred C shares, £0.000008 par value; 1 share authorized, issued
and outstanding at June 30, 2022 and December 31, 2021 |
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
848,370 |
|
|
|
843,108 |
|
Accumulated other comprehensive loss |
|
(33,510 |
) |
|
|
(8,570 |
) |
Accumulated deficit |
|
(600,461 |
) |
|
|
(521,340 |
) |
Total shareholders'
equity |
|
214,521 |
|
|
|
313,320 |
|
Total liabilities and
shareholders' equity |
$ |
313,976 |
|
|
$ |
405,560 |
|
|
|
|
|
|
|
|
|
Condensed Consolidated Statements of
Operations and Comprehensive Loss (In thousands, except
share and per share amounts)
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
|
2022 |
|
2021 |
|
2022 |
|
2021 |
Grant income |
$ |
— |
|
|
$ |
138 |
|
|
$ |
166 |
|
|
$ |
407 |
|
License revenue |
|
— |
|
|
|
1,507 |
|
|
|
— |
|
|
|
1,507 |
|
|
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
Research and development |
|
(38,212 |
) |
|
|
(32,131 |
) |
|
|
(72,175 |
) |
|
|
(62,862 |
) |
General and
administrative |
|
(8,269 |
) |
|
|
(7,237 |
) |
|
|
(16,256 |
) |
|
|
(15,975 |
) |
Loss on disposal of leasehold
improvements |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(672 |
) |
Total operating
expenses, net |
|
(46,481 |
) |
|
|
(37,723 |
) |
|
|
(88,265 |
) |
|
|
(77,595 |
) |
Other (expense)
income: |
|
|
|
|
|
|
|
Other expense, net |
|
(1,331 |
) |
|
|
(1,849 |
) |
|
|
(471 |
) |
|
|
(1,011 |
) |
Interest income |
|
89 |
|
|
|
42 |
|
|
|
117 |
|
|
|
85 |
|
Interest expense |
|
(1,810 |
) |
|
|
— |
|
|
|
(3,599 |
) |
|
|
— |
|
Total other (expense)
income, net |
|
(3,052 |
) |
|
|
(1,807 |
) |
|
|
(3,953 |
) |
|
|
(926 |
) |
Net loss before income
tax |
|
(49,533 |
) |
|
|
(39,530 |
) |
|
|
(92,218 |
) |
|
|
(78,521 |
) |
Income tax benefit |
|
7,474 |
|
|
|
6,357 |
|
|
|
13,098 |
|
|
|
12,081 |
|
Net loss attributable
to ordinary shareholders |
|
(42,059 |
) |
|
|
(33,173 |
) |
|
|
(79,120 |
) |
|
|
(66,440 |
) |
Other comprehensive
(loss) income: |
|
|
|
|
|
|
|
Foreign currency exchange
translation adjustment |
|
(17,485 |
) |
|
|
1,542 |
|
|
|
(24,941 |
) |
|
|
2,815 |
|
Total comprehensive
loss |
$ |
(59,544 |
) |
|
$ |
(31,631 |
) |
|
$ |
(104,061 |
) |
|
$ |
(63,625 |
) |
|
|
|
|
|
|
|
|
Basic and diluted net loss per
ordinary share |
$ |
(0.46 |
) |
|
$ |
(0.47 |
) |
|
$ |
(0.87 |
) |
|
$ |
(1.00 |
) |
Weighted-average basic and
diluted ordinary shares |
|
90,931,964 |
|
|
|
70,832,077 |
|
|
|
90,923,119 |
|
|
|
66,663,003 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conference CallManagement will
host a conference call and webcast at 8:30 am ET/1:30 pm BST
to discuss the Company’s financial results and provide a general
business update. Conference call participants should pre-register
using this link to receive the dial-in numbers and a
personal PIN, which are required to access the conference call. The
conference call system has changed, so please make sure you dial in
15 minutes before to ensure timely access to the call.
A simultaneous audio webcast and replay will be
accessible on the events section of Autolus’ website.
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the Company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information,
please visit www.autolus.com.
About
obe-cel (AUTO1)Obe-cel is a CD19 CAR T cell
investigational therapy designed to overcome the limitations in
clinical activity and safety compared to current CD19 CAR T cell
therapies. Designed to have a fast target binding off-rate to
minimize excessive activation of the programmed T cells, obe-cel
may reduce toxicity and be less prone to T cell exhaustion, which
could enhance persistence and improve the ability of the programmed
T cells to engage in serial killing of target cancer cells. In
collaboration with Autolus’ academic partner, UCL, obe-cel is
currently being evaluated in a Phase 1 clinical trials for B-NHL.
Autolus has progressed obe-cel to the FELIX trial, a pivotal trial
for adult ALL.
About obe-cel
FELIX clinical trialAutolus’ Phase 1b/2 clinical
trial of obe-cel is enrolling adult patients with relapsed /
refractory B-precursor ALL. The trial had a Phase 1b component
prior to proceeding to the single arm, Phase 2 clinical trial. The
primary endpoint is overall response rate, and the secondary
endpoints include duration of response, MRD negative CR rate and
safety. The trial is designed to enroll approximately 100 patients
across 30 of the leading academic and non-academic centers in the
United States, United Kingdom and Europe.
[NCT04404660]
About AUTO1/22AUTO1/22 is a
novel dual targeting CAR T cell based therapy candidate based on
obe-cel. It is designed to combine the enhanced safety, robust
expansion & persistence seen with the fast off rate CD19 CAR
from obe-cel with a high sensitivity CD22 CAR to reduce antigen
negative relapses. This product candidate is currently in a Phase 1
clinical trial for patients with r/r pediatric ALL.
[NCT02443831]
About AUTO4AUTO4 is a
programmed T cell product candidate in clinical development for T
cell lymphoma, a setting where there are currently no approved
programmed T cell therapies. AUTO4 is specifically designed to
target TRBC1 derived cancers, which account for approximately 40%
of T cell lymphomas, and is a complement to the AUTO5 T cell
product candidate, which is in pre-clinical development.
About AUTO5AUTO5 is a
programmed T cell product candidate in pre-clinical development for
T cell lymphoma, a setting where there are currently no approved
programmed T cell therapies. AUTO5 is specifically designed to
target TRBC2 derived cancers, which account for approximately 60%
of T cell lymphomas, and is a complement to the AUTO4 T cell
product candidate currently in clinical development.
About AUTO6NGAUTO6NG is a next
generation programmed T cell product candidate in pre-clinical
development. AUTO6NG builds on preliminary proof of concept
data from AUTO6, a CAR targeting GD2-expression cancer cell
currently in clinical development for the treatment of
neuroblastoma. AUTO6NG incorporates additional cell programming
modules to overcome immune suppressive defense mechanisms in the
tumor microenvironment, in addition to endowing the CAR T cells
with extended persistence capacity. AUTO6NG is currently in
pre-clinical development for the potential treatment of both
neuroblastoma and other GD2-expressing solid tumors.
About AUTO8AUTO8 is our
next-generation product candidate for multiple myeloma which
comprises two independent CARs for the multiple myeloma targets,
BCMA and CD19. We have developed an optimized BCMA CAR which is
designed for improved killing of target cell that express BCMA at
low levels. This has been combined with fast off rate CD19 CAR from
obe-cel. We believe that the design of AUTO8 has the potential
to induce deep and durable responses and extend the durability of
effect over other BCMA CARs currently in development.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
statements that are not historical facts, and in some cases can be
identified by terms such as "may," "will," "could," "expects,"
"plans," "anticipates," and "believes." These statements include,
but are not limited to, statements regarding the development of
Autolus’ product candidate pipeline and achievement of expected
near- and long-term milestones; the development of the obe-cel
program including planned readouts after the completed futility
analysis and completion of patient enrollment; the future clinical
development, efficacy, safety and therapeutic potential of its
other product candidates such as AUTO1/22, AUTO4. AUTO5, AUTO6NG,
and AUTO8, including progress, expectations as to the reporting of
data, conduct and timing and potential future clinical activity and
milestones; expectations regarding regulatory approval process for
any product candidates; Autolus’ eligibility for potential
milestone and royalty payments, and the Company’s anticipated cash
runway. Any forward-looking statements are based on management's
current views and assumptions and involve risks and uncertainties
that could cause actual results, performance, or events to differ
materially from those expressed or implied in such statements.
These risks and uncertainties include, but are not limited to, the
risks that Autolus’ preclinical or clinical programs do not advance
or result in approved products on a timely or cost effective basis
or at all; the results of early clinical trials are not always
being predictive of future results; the cost, timing and results of
clinical trials; that many product candidates do not become
approved drugs on a timely or cost effective basis or at all; the
ability to enroll patients in clinical trials; possible safety and
efficacy concerns; and the impact of the ongoing COVID-19 pandemic
on Autolus’ business. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause Autolus’ actual results to differ from those contained in the
forward-looking statements, see the section titled "Risk Factors"
in Autolus' Annual Report on Form 20-F filed with the Securities
and Exchange Commission on March 10, 2022, as well as discussions
of potential risks, uncertainties, and other important factors in
Autolus' subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Autolus undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise, except as required by
law.
Contact:
Olivia Manser+44 (0) 7780
471568o.manser@autolus.com
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-917-513-5303susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024